国内硼替佐米联合化疗方案治疗多发性骨髓瘤的疗效及安全性的Meta分析

Efficacy and Safety of Bortezomib Combined with Other Chemotherapy Drugs in The Treatment of Multiple Myeloma in China:A Meta-analysis

目的:评价硼替佐米进入国内十年来治疗多发性骨髓瘤(multiple myeloma,MM)的疗效和安全性。方法:计算机检索中国学术期刊全文数据库(CNKI)、维普科技期刊全文数据库(VIP)、万方数据库,检索年限为2005至2015年。纳入以硼替佐米为主联合化疗方案治疗MM的随机对照试验(RCT),进行文献质量评价与数据提取后,使用Stata SE 12.0软件进行Meta分析。结果:共纳入11个RCT,包括423例患者,纳入的文献不存在异质性,无发表偏倚。Meta分析结果显示,硼替佐米联合化疗方案与传统化疗方案(单用MPT、VAD、M2、CDT方案)相比,其治疗MM的总有效率(RR=1.33,95%CI:1.20~1.48)与缓解率(RR=1.48,95%CI:1.29~1.69)均较高,差异均有统计学意义(P<0.05)。结论:与传统化疗方案相比,硼替佐米联合化疗方案能提高MM治疗的总有效率与缓解率,不良反应可耐受。

Objective： To assess the efficacy and safety of bortezomib on patients with multiple myeloma in rencent ten years in China. Methods： Randomized controlled trials （RCT） of bortezomib in the treatment of multiple myeloma were collected from CNKI, VIP and Wanfang Databases by 2 independent researchers. After literature screening, quality evaluation and data extraction, StataSE 12.0 software was used for meta-analysis. Results： A total of 11 RCT with 423 cases included in this meta- analysis. There were no heterogeneity and no publication bias existed. In the treatment of mutiple myeloma, compared with traditional chemotherapy drugs （MPT, VAD, M2, CDT） , bortezomib combined with other chemotherapy drugs significantly increased the total effective rate （RR=1.33, 95% CI： 1.20-1.48） and the remission rate （RR=1.48, 95% CI： 1.29-1.69） . Conclusion： Compared with traditional chemotherapy drugs, bortezomib combined with other drugs can improve the total effective rate and remission rate in the treatment of multiple myeloma, and the adverse reactions can be tolerated.